Long-term assessment of prostate cancer progression free survival: Evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis

Prostate

Volumn 68, Issue 16, 2008, Pages 1806-1815

  Veltri, Robert W ^a   Isharwal, Sumit ^a   Miller, M Craig ^b   Epstein, Jonathan I ^a   Mangold, Leslie A ^a   Humphreys, Elizabeth ^a   Partin, Alan W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

BCL2; CD31; Chromogranin a; Her 2 neu; Ki 67; Nuclear shape; PCNA; Prognosis; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; CD31 ANTIGEN; CHROMOGRANIN A; CYCLINE; KI 67 ANTIGEN; PROTEIN BCL 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; CHILD; CORRELATION COEFFICIENT; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; AGED; APOPTOSIS; CELL NUCLEUS; CELL PROLIFERATION; COHORT ANALYSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; FOLLOW UP; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR; REGRESSION ANALYSIS;

AGED; ANTIGENS, CD31; APOPTOSIS; CELL NUCLEUS; CELL PROLIFERATION; CHROMOGRANIN A; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; REGRESSION ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 56049094811     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20848     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA: Cancer J Clin 2008;58(2):71-96.
2. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152(5 Pt 2):1837-1842.
3. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results. J Urol 1998;160(6 Pt 2):2428-2434.
4. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294(4):433-439.
5. Freedland SJ, Mangold LA, Walsh PC, Partin AW. The prostatic specific antigen era is alive and well: Prostatic specific antigen and biochemical progression following radical prostatectomy. J Urol 2005;174(4 Pt 1):1276-1281; discussion 1281; author reply 1281.
6. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-1597.
7. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC, Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169(2):517-523.
8. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349(4):366-381.
9. Nelson WG, DeWeese TL, DeMarzo AM. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 2002;21(1):3-16.
10. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol 2004;171(2 Pt 2):S36-S40.
11. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361(9361): 955-964.
12. Veltri RW. Molecular biology of serum biomarkers of prostate cancer. In: Kirby RS, Partin AW, Feneley MR, Parsons JK, editors. Prostate cancer: Principles and practice. London & New York: Taylor & Francis; 2006. pp 269-284.
13. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: Current and future diagnostic markers. Clin Cancer Res 2004;10(12 Pt 1):3943-3953.
14. Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, Boccon-Gibod L, Ekman P. Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol 2005(216):64-81.
15. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 1992;70(1 Suppl):254-268.
16. Epstein JI. Pathologic assessment of the surgical specimen. Urol Clin N Am 2001;28(3):567-594.
17. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293(17):2095-2101.
18. Carmichael MJ, Veltri RW, Partin AW, Miller MC, Walsh PC, Epstein JI. Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol 1995;153(3 Pt 2):1015-1019.
19. Veltri RW, Partin AW, Epstein JE, Marley GM, Miller CM, Singer DS, Patton KP, Criley SR, Coffey DS. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem 1994;19:249-258.
20. Stein GS, Montecino M, van Wijnen AJ, Stein JL, Lian JB. Nuclear structure-gene expression interrelationships: Implications for aberrant gene expression in cancer. Cancer Res 2000;60(8):2067-2076.
21. Diamond DA, Berry SJ, Umbricht C, Jewett HJ, Coffey DS. Computerized image analysis of nuclear shape as a prognostic factor for prostatic cancer. Prostate 1982;3(4):321-332.
22. Epstein JI, Berry SJ, Eggleston JC. Nuclear roundness factor. A predictor of progression in untreated Stage A2 prostate cancer. Cancer 1984;54(8):1666-1671.
23. Partin AW, Walsh AC, Pitcock RV, Mohler JL, Epstein JI, Coffey DS. A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: A critical analysis. J Urol 1989;142(5):1254-1258.
24. Veltri RW, Khan MA, Miller MC, Epstein JI, Mangold LA, Walsh PC, Partin AW. Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate. Clin Cancer Res 2004;10(10):3465-3473.
25. Veltri RW, Miller MC, Isharwal S, Marlow C, Makarov DV, Partin AW. Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry. Cancer Epidemiol Biomarkers Prev 2008;17(1):102-110.
26. Sauerbrei W. The use of resampling methods to simplify regression models in medical statistics. Appl Statist 1999;48(3):313-329.
27. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1996;69:135-174.
28. Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 1993;24(2):220-226.
29. Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1997;79(4):772-779.
30. Rubin MA, Buyyounouski M, Bagiella E, Sharir S, Neugut A, Benson M, de la Taille A, Katz AE, Olsson CA, Ennis RD. Microvessel density in prostate cancer: Lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology 1999;53(3):542-547.
31. Gettman MT, Bergstralh EJ, Blute M, Zincke H, Bostwick DG. Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: Lack of significance for microvessel density analysis. Urology 1998;51(1):79-85.
32. Cohen RJ, Glezerson G, Haffejee Z. Neuro-endocrine cells - A new prognostic parameter in prostate cancer. British journal of urology 1991;68(3):258-262.
33. Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996;27(7):683-687.
34. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002;167(2 Pt 1):512-515.
35. Berruti A, Mosca A, Porpiglia F, Bollito E, Tucci M, Vana F, Cracco C, Torta M, Russo L, Cappia S, Saini A, Angeli A, Papotti M, Scarpa RM, Dogliotti L. Chromogranin A expression in patients with hormone naive prostate cancer predicts the development of hormone refractory disease. J Urol 2007;178 (3 Pt 1):838-843; quiz 1129.
36. Ahlegren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson P. Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume. Urology 2000;56(6):1011-1015.
37. Bubendorf L, Tapia C, Gasser TC, Casella R, Grunder B, Moch H, Mihatsch MJ, Sauter G. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 1998;29(9):949-954.
38. Khoo VS, Pollack A, Cowen D, Joon DL, Patel N, Terry NH, Zagars GK, von Eschenbach AC, Meistrich ML, Troncoso P. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate 1999;41(3):166-172.
39. Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996;156(3):1064-1068.
40. Cher ML, Chew K, Rosenau W, Carroll PR. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate 1995;26(2):87-93.
41. Rubio J, Ramos D, Lopez-Guerrero JA, Iborra I, Collado A, Solsona E, Almenar S, Llombart-Bosch A. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol 2005;48(5):745-751.
42. Borre M, Stausbol-Gron B, Nerstrom B, Overgaard J. Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly. Prostate Cancer Prostatic Dis 1998;1(5):268-275.
43. Stackhouse GB, Sesterhenn IA, Bauer JJ, Mostofi FK, Connelly RR, Srivastava SK, Moul JW. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 1999;162(6):2040-2045.
44. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, NY) 1987;235(4785):177-182.
45. Myers RB, Srivastava S, Oelschlager DK, Grizzle WE. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 1994;86(15):1140-1145.
46. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000;92(23):1918-1925.
47. Calvo BF, Levine AM, Marcos M, Collins QF, Iacocca MV, Caskey LS, Gregory CW, Lin Y, Whang YE, Earp HS, Mohler JL. Human epidermal receptor-2 expression in prostate cancer. Clin Cancer Res 2003;9(3):1087-1097.
48. Savinainen KJ, Saramaki OR, Linja MJ, Bratt O, Tammela TL, Isola JJ, Visakorpi T. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol 2002;160(1):339-345.
49. Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B, Bartlett JM. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res 2006;12(1):123-130.
50. Osman I, Mikhail M, Shuch B, Clute M, Cheli CD, Ghani F, Thiel RP, Taneja SS. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J Urol 2005;174(6):2174-2177.
51. Domingo-Domenech J, Fernandez PL, Filella X, Martinez-Fernandez A, Molina R, Fernandez E, Alcaraz A, Codony J, Gascon P, Mellado B. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann Oncol 2008;19(2):269-275.